Limits...
Ectopic expression of follicle-stimulating hormone receptors in thyroid tumors.

Pawlikowski M, Jaranowska M, Pisarek H, Kubiak R, Fuss-Chmielewska J, Winczyk K - Arch Med Sci (2015)

Bottom Line: However, recently we have found FSHR immunostaining in pituitary adenomas, adrenal tumors and neuroendocrine tumors (carcinoids).Normal thyroid follicles do not show immunopositivity for FSHR.In about 40% of samples FSHR immunoreactivity can be observed also in the endothelia of intrathyroidal blood vessels.

View Article: PubMed Central - PubMed

Affiliation: Department of Immunoendocrinology, Chair of Endocrinology, Medical University of Lodz, Lodz, Poland.

ABSTRACT

Introduction: In normal conditions follicle-stimulating hormone receptors (FSHR) are expressed in the ovary and the testis. They can also be expressed in gonadal tumors. However, recently we have found FSHR immunostaining in pituitary adenomas, adrenal tumors and neuroendocrine tumors (carcinoids). The aim of this study was to determine whether the same occurs in thyroid tumors.

Material and methods: Thirty-six samples of surgically excised thyroids were examined. Follicle-stimulating hormone receptors immunostaining was performed on paraffin sections using the rabbit anti-human FSHR polyclonal antibody raised against a 1-190 amino acid sequence from the human FSHR (sc-13935, Santa Cruz).

Results: Normal thyroid follicles do not show immunopositivity for FSHR. The same concerns the majority of benign lesions, diagnosed as hyperplasia nodularis or thyroid adenomas. However, positive FSHR immunostaining in some follicles was observed. In all but one thyroid cancer (15 papillary, 10 follicular cancers and one case of anaplastic thyroid cancer) 10-100% of tumor cells exhibit positive FSHR immunostaining. In about 40% of samples FSHR immunoreactivity can be observed also in the endothelia of intrathyroidal blood vessels. This immunopositivity was more frequent in the samples of thyroid cancers (13/27) than in benign lesions (2/9).

Conclusions: Ectopic positive FSHR immunostaining is also present in thyroid cancers, and, to a lesser degree, in benign lesions but not in the normal thyroid epithelium.

No MeSH data available.


Related in: MedlinePlus

Positive FSHR immunostaining in papillary cancer
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4697062&req=5

Figure 0003: Positive FSHR immunostaining in papillary cancer

Mentions: Normal thyroid follicles do not show immunopositivity for FSHR (Figure 1). The same concerns the majority of benign lesions, diagnosed as hyperplasia nodularis or thyroid follicular adenomas. However, FSHR immunoreactivity is positive only in a small proportion of follicles (Figure 2). In all but one papillary cancers and in all follicular cancers 10–100% of tumor cells exhibit positive FSHR immunostaining (Figures 3, 4). In 1 case of anaplastic thyroid cancer all tumor cells are immunopositive with anti-FSHR antibody (Figure 5). In 15/36 (approx. 40%) samples FSHR immunostaining can be observed also in the walls of intrathyroidal blood vessels, particularly in the endothelium (Figure 6).


Ectopic expression of follicle-stimulating hormone receptors in thyroid tumors.

Pawlikowski M, Jaranowska M, Pisarek H, Kubiak R, Fuss-Chmielewska J, Winczyk K - Arch Med Sci (2015)

Positive FSHR immunostaining in papillary cancer
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4697062&req=5

Figure 0003: Positive FSHR immunostaining in papillary cancer
Mentions: Normal thyroid follicles do not show immunopositivity for FSHR (Figure 1). The same concerns the majority of benign lesions, diagnosed as hyperplasia nodularis or thyroid follicular adenomas. However, FSHR immunoreactivity is positive only in a small proportion of follicles (Figure 2). In all but one papillary cancers and in all follicular cancers 10–100% of tumor cells exhibit positive FSHR immunostaining (Figures 3, 4). In 1 case of anaplastic thyroid cancer all tumor cells are immunopositive with anti-FSHR antibody (Figure 5). In 15/36 (approx. 40%) samples FSHR immunostaining can be observed also in the walls of intrathyroidal blood vessels, particularly in the endothelium (Figure 6).

Bottom Line: However, recently we have found FSHR immunostaining in pituitary adenomas, adrenal tumors and neuroendocrine tumors (carcinoids).Normal thyroid follicles do not show immunopositivity for FSHR.In about 40% of samples FSHR immunoreactivity can be observed also in the endothelia of intrathyroidal blood vessels.

View Article: PubMed Central - PubMed

Affiliation: Department of Immunoendocrinology, Chair of Endocrinology, Medical University of Lodz, Lodz, Poland.

ABSTRACT

Introduction: In normal conditions follicle-stimulating hormone receptors (FSHR) are expressed in the ovary and the testis. They can also be expressed in gonadal tumors. However, recently we have found FSHR immunostaining in pituitary adenomas, adrenal tumors and neuroendocrine tumors (carcinoids). The aim of this study was to determine whether the same occurs in thyroid tumors.

Material and methods: Thirty-six samples of surgically excised thyroids were examined. Follicle-stimulating hormone receptors immunostaining was performed on paraffin sections using the rabbit anti-human FSHR polyclonal antibody raised against a 1-190 amino acid sequence from the human FSHR (sc-13935, Santa Cruz).

Results: Normal thyroid follicles do not show immunopositivity for FSHR. The same concerns the majority of benign lesions, diagnosed as hyperplasia nodularis or thyroid adenomas. However, positive FSHR immunostaining in some follicles was observed. In all but one thyroid cancer (15 papillary, 10 follicular cancers and one case of anaplastic thyroid cancer) 10-100% of tumor cells exhibit positive FSHR immunostaining. In about 40% of samples FSHR immunoreactivity can be observed also in the endothelia of intrathyroidal blood vessels. This immunopositivity was more frequent in the samples of thyroid cancers (13/27) than in benign lesions (2/9).

Conclusions: Ectopic positive FSHR immunostaining is also present in thyroid cancers, and, to a lesser degree, in benign lesions but not in the normal thyroid epithelium.

No MeSH data available.


Related in: MedlinePlus